Last Updated: November 16, 2026

List of Excipients in Branded Drug SIRTURO

« Back to Dashboard


Sirturo Excipient Strategy and Commercial Opportunities for Bedaquiline

Last updated: October 2, 2026

Sirturo is Janssen’s bedaquiline fumarate product for multidrug-resistant tuberculosis. Its excipient strategy differs by dosage form: the 100 mg immediate-release tablet prioritizes dose uniformity, mechanical strength, and dissolution, while the 20 mg dispersible tablet prioritizes pediatric administration, rapid dispersion, palatability, and flexible dosing. The strongest commercial opportunities are in pediatric dispersible delivery, taste masking, qualified excipient supply, generic formulation support, and region-specific manufacturing.

What dosage forms and excipients does Sirturo use?

Sirturo is marketed primarily as 100 mg tablets and 20 mg dispersible tablets. FDA-approved labeling identifies different excipient systems for the two presentations. Exact composition should be controlled against the current FDA label and the applicable product monograph because manufacturers can update inactive-ingredient information through regulatory supplements. (U.S. Food and Drug Administration [FDA], 2024; DailyMed, 2024)

Sirturo 100 mg tablet

The 100 mg tablet uses conventional immediate-release solid-dose excipients. The listed excipient categories include:

Excipient function Representative excipients identified in product information
Diluent and compressibility Lactose monohydrate, microcrystalline cellulose
Disintegration Croscarmellose sodium
Binder or film-forming support Hypromellose
Lubrication Magnesium stearate
Flow and anti-caking control Colloidal silicon dioxide
Wetting or dispersion support Polysorbate 20 and related formulation components identified in labeling

The tablet is administered with food. This is clinically important because food increases bedaquiline exposure, and the commercial formulation is not designed to be administered independently of the product’s food instructions. (FDA, 2024)

Sirturo 20 mg dispersible tablet

The 20 mg dispersible tablet is designed for pediatric patients and can be dispersed in water before administration. Its excipient architecture is more complex because it must meet four requirements:

  1. Rapid dispersion in a small volume of water.
  2. Acceptable taste for children.
  3. Dose flexibility through multiple-tablet administration.
  4. Physical stability during storage and transport.

The formulation includes common pediatric solid-dose components such as mannitol, microcrystalline cellulose, croscarmellose sodium, crospovidone or related disintegrant functionality, colloidal silicon dioxide, magnesium stearate, sweetening agents, and flavoring components. The precise inactive-ingredient list should be taken from the current product label for each jurisdiction. (FDA, 2024; DailyMed, 2024)

Which excipients are commercially important for Sirturo?

The highest-value excipient opportunities are not necessarily the ingredients used at the largest weight percentage. Commercial value is concentrated in ingredients that control bioavailability, taste, dispersion, manufacturability, or regulatory substitution risk.

Lactose and microcrystalline cellulose

Lactose monohydrate and microcrystalline cellulose support tablet mass, compressibility, and manufacturing throughput. Both are widely available, so they are unlikely to create durable exclusivity. Their commercial importance comes from grade selection and process performance.

A generic manufacturer may need to evaluate:

  • Particle-size distribution.
  • Moisture content.
  • Bulk and tapped density.
  • Compactibility under high-speed compression.
  • Compatibility with bedaquiline fumarate.
  • Impact on dissolution after storage.
  • Supplier-to-supplier variability.

A direct excipient substitution can alter tablet hardness, friability, disintegration, and dissolution even when the chemical identity remains unchanged.

Croscarmellose sodium and crospovidone

Disintegrants are central to the Sirturo formulation strategy. The 100 mg tablet requires reliable breakup after swallowing. The 20 mg dispersible tablet requires rapid dispersion in water without excessive aggregation or sedimentation.

Supplier opportunities exist in controlled-particle-size and high-functionality grades that provide:

  • Faster wetting.
  • Lower dispersion time.
  • More consistent tablet disintegration.
  • Lower sensitivity to compression force.
  • Better performance across humidity conditions.

These excipients are generally substitutable from a patent perspective, but substitution can create formulation-development and bioequivalence risk.

Polysorbate and wetting agents

Bedaquiline is a highly lipophilic compound. Wetting and dispersion behavior therefore affect dissolution and exposure. Surfactant selection can influence:

  • Initial dissolution rate.
  • Drug wetting.
  • Powder segregation.
  • Tablet lubrication.
  • Stability under heat and humidity.
  • In vitro-in vivo correlation.

A supplier that can provide a low-peroxide, low-impurity surfactant grade with robust global documentation may have a stronger commercial position than a commodity supplier. For a generic version, surfactant substitution would require comparative dissolution and stability work and could trigger additional regulatory scrutiny if the change materially affects bioavailability.

Mannitol

Mannitol is particularly relevant to the dispersible tablet because it contributes to mouthfeel, sweetness perception, tablet bulk, and low-hygroscopicity performance. Compared with some other polyols, mannitol can provide a cleaner taste and a more stable solid form.

Commercial differentiation may come from:

  • Direct-compression mannitol grades.
  • Low-metal and low-endotoxin specifications.
  • Controlled particle size.
  • Improved flow and compactibility.
  • Regional pharmacopeial compliance.
  • Supply security for pediatric products.

Sweeteners and flavor systems

The pediatric dispersible tablet creates the clearest excipient opportunity. Taste masking is difficult because bedaquiline has an unfavorable taste profile and the product may be dispersed in water before administration.

Potential technologies include:

  • Ion-exchange resin complexes.
  • Polymer coating of drug particles.
  • Lipid or wax barriers.
  • Cyclodextrin-based systems.
  • Multiparticulate taste-masked granules.
  • Flavor systems optimized for short residence time in the mouth.

The commercial challenge is to reduce bitterness without slowing drug release or changing exposure. A taste-masking technology that requires a new solid-state form, coated particle, or complex may increase development cost and regulatory burden.

What formulation patents could affect Sirturo excipient opportunities?

Excipient suppliers should distinguish between three types of intellectual property:

IP category Typical commercial relevance
Bedaquiline compound patents Protect the active pharmaceutical ingredient and may control the earliest generic entry date
Method-of-use patents Cover treatment of drug-resistant tuberculosis, combination regimens, or dosing protocols
Formulation and dosage-form patents May cover dispersible tablets, pediatric administration, particle engineering, taste masking, or specific excipient combinations

Excipient-specific patents are not automatically listed in the FDA Orange Book. Orange Book listings generally focus on patents asserted to cover the approved drug, its formulation or composition, and approved methods of use. A supplier’s own excipient technology may be protected outside the Orange Book through formulation patents, process patents, trade secrets, or contractual controls. (FDA, 2024a)

The most commercially relevant formulation questions are:

  • Whether a pediatric dispersible dosage form is separately claimed.
  • Whether a particular taste-masking architecture is claimed.
  • Whether the composition requires a defined surfactant or disintegrant combination.
  • Whether the manufacturing process creates a protected particle morphology.
  • Whether the patent claims cover the excipient identity or only performance parameters.

A supplier that relies on a patented taste-masking platform should conduct a freedom-to-operate analysis across the United States, European Union, India, China, Brazil, and South Africa. MDR-TB demand is geographically concentrated, and patent risk can vary materially by country.

When does Sirturo lose exclusivity and how does that affect excipient suppliers?

Sirturo’s commercial exclusivity depends on several separate events:

  1. FDA regulatory exclusivity.
  2. Listed U.S. patents.
  3. Pediatric exclusivity.
  4. Patent settlements or licenses.
  5. Local patent rights outside the United States.
  6. Regulatory approval of competing products.

The active compound and treatment methods may have patent protection periods that differ from the protection for pediatric or dispersible formulations. A single “Sirturo expiration date” is therefore inadequate for commercial planning.

What is the Orange Book status of Sirturo?

The Orange Book is the controlling source for current U.S. listed patents and exclusivity entries. Sirturo’s listed patents should be checked by the exact product, dosage form, and current edition because entries can be added, delisted, corrected, or affected by pediatric exclusivity. (FDA, 2024a)

An excipient supplier should not assume that the absence of an excipient name from the Orange Book eliminates risk. The relevant patent may claim:

  • The complete pharmaceutical composition.
  • A defined weight ratio of bedaquiline and excipient.
  • A dispersible dosage form.
  • A pediatric dosing method.
  • A manufacturing process.
  • A taste-masked particle.

Are Paragraph IV challenges relevant to Sirturo?

A generic applicant submitting an abbreviated new drug application may use a Paragraph IV certification against an Orange Book-listed patent. A challenge could target the active compound, formulation, or method-of-use claims. Excipient manufacturers become commercially relevant when the proposed generic formulation requires a non-infringing substitute for a protected formulation feature.

The commercial consequences are direct:

  • A successful Paragraph IV challenge can accelerate demand for generic-grade excipients.
  • A settlement can delay commercial launch and extend the supplier’s preparation window.
  • A formulation patent that survives litigation can preserve demand for the reference-product excipient architecture.
  • A non-infringing generic may create demand for alternative disintegrants, surfactants, binders, or taste-masking systems.

What generic launch scenarios exist for Sirturo?

Scenario 1: Adult tablet-only generic

This is the most straightforward opportunity. A generic manufacturer can focus on the 100 mg immediate-release tablet and replicate core quality attributes using conventional excipients.

Likely supplier requirements include:

  • Consistent lactose and microcrystalline cellulose grades.
  • High-functionality disintegrants.
  • Stable lubricant performance.
  • Robust dissolution across batches.
  • DMF or equivalent regulatory documentation.
  • Multi-region GMP compliance.

Scenario 2: Pediatric dispersible generic

This opportunity is more technically demanding. The product must demonstrate acceptable dispersion, dose recovery, stability, and palatability. A manufacturer may need clinical or comparative data beyond routine adult-tablet development, depending on the regulatory pathway and jurisdiction.

The best-positioned excipient suppliers will offer integrated services covering:

  • Formulation screening.
  • Taste evaluation.
  • Dispersibility testing.
  • Stability studies.
  • Scale-up support.
  • Regulatory documentation.
  • Commercial supply assurance.

Scenario 3: Regional pediatric product

Some markets may favor dispersible tablets, oral granules, or powder-for-suspension presentations. A regional product can create demand for localized flavor systems, lower-cost fillers, and packaging that tolerates high humidity.

This scenario is commercially attractive in countries with high MDR-TB burden but limited access to branded products. However, pricing pressure is likely to be substantial, and suppliers will need to compete on total delivered cost rather than formulation novelty alone.

How strong is the Sirturo formulation opportunity?

The formulation opportunity is moderate for the adult tablet and stronger for pediatric delivery.

Factor 100 mg tablet 20 mg dispersible tablet
Formulation complexity Moderate High
Excipient differentiation Limited Significant
Taste-masking requirement Low to moderate High
Generic development risk Moderate High
Supplier switching difficulty Moderate High
Potential for proprietary technology Limited Meaningful
Global pediatric demand Lower Higher strategic value

The 100 mg product is more exposed to commodity excipient competition. The 20 mg dispersible product has greater potential for differentiated excipient systems because performance depends on taste, dispersion, dose recovery, and pediatric acceptability.

What commercial opportunities exist for excipient manufacturers?

Qualified second-source supply

The immediate opportunity is dual sourcing for:

  • Mannitol.
  • Microcrystalline cellulose.
  • Croscarmellose sodium.
  • Crospovidone.
  • Colloidal silicon dioxide.
  • Magnesium stearate.
  • Pharmaceutical-grade surfactants.
  • Flavor and sweetener systems.

A supplier that already has global GMP approvals and a strong change-control system can reduce customer qualification time.

Pediatric taste-masking platforms

The highest-margin opportunity is a taste-masking platform that can be adapted to bedaquiline without compromising dissolution. The platform must support scale-up and avoid creating a new intellectual-property conflict.

Contract development and manufacturing

Formulation-development companies can offer a package for generic or nonprofit manufacturers:

  • Excipient compatibility screening.
  • Design-of-experiments studies.
  • Dispersible-tablet optimization.
  • Comparative dissolution.
  • Stability programs.
  • Regulatory CMC support.
  • Pilot-scale manufacturing.

Manufacturing and IP barriers

Bedaquiline’s physicochemical properties, food effect, dosing schedule, and pediatric administration requirements create barriers beyond simple tablet compression. Key manufacturing risks include:

  • Content uniformity at low-dose-per-unit presentation.
  • Powder segregation.
  • Lubrication sensitivity.
  • Moisture-related dissolution changes.
  • Taste-masking impact on release.
  • Inadequate dispersion in the labeled water volume.
  • Stability of flavor and sweetener systems.

These barriers favor suppliers that can provide application data rather than only raw materials.

How does Sirturo compare with other MDR-TB drugs?

Sirturo differs from many MDR-TB products because bedaquiline has a distinct lipophilic profile and a clinically relevant food effect. In contrast, excipient selection for drugs such as linezolid, levofloxacin, or clofazimine may place different emphasis on dose size, solubility, taste, or release behavior.

Product Primary excipient opportunity
Sirturo Pediatric dispersion, taste masking, wetting, dissolution control
Linezolid Pediatric suspension, taste masking, high-dose oral delivery
Levofloxacin Oral solution, pediatric taste masking, tablet robustness
Clofazimine Lipid-based delivery, solubility and bioavailability support
Pretomanid Tablet manufacturability and combination-product supply

Sirturo’s commercial value for excipient suppliers is strongest where the supplier can address pediatric administration and bioperformance rather than provide a standard filler.

What is the FDA regulatory status of Sirturo?

Sirturo was approved by FDA for pulmonary MDR-TB in adults under the accelerated approval pathway and later received broader regulatory support as clinical evidence matured. The product is also used in pediatric populations under age- and weight-specific labeling. The applicable indication, dosage form, and patient population should be confirmed against the current FDA prescribing information. (FDA, 2024)

For generic development, the regulatory strategy should address:

  • Reference listed drug selection.
  • Product-specific bioequivalence requirements.
  • Food-effect considerations.
  • Comparative dissolution.
  • Pediatric dosage-form equivalence.
  • Excipient safety in children.
  • Labeling and administration instructions.
  • Global variation in inactive-ingredient standards.

Key Takeaways

  • Sirturo’s adult tablet uses a conventional immediate-release excipient platform.
  • The 20 mg dispersible tablet creates the stronger commercial opportunity because taste, dispersion, and pediatric acceptability are harder to replicate.
  • Mannitol, disintegrants, wetting agents, and taste-masking systems are the most strategically important excipient categories.
  • Generic entry risk depends on the complete patent and exclusivity record, not on a single expiration date.
  • Excipient substitutions can affect dissolution, bioavailability, stability, and pediatric acceptability.
  • The best supplier opportunities are qualified second sourcing, pediatric taste masking, formulation development, and regional supply support.
  • Orange Book review, patent-family analysis, and formulation freedom-to-operate work are required before commercial launch planning.

FAQs About Sirturo Excipients and Generic Formulation

Can Sirturo tablets be reformulated with different excipients?

Yes, a generic manufacturer can use different excipients if the finished product meets applicable quality, bioequivalence, safety, and regulatory requirements. Changes that affect dissolution or exposure create higher development risk.

Which Sirturo dosage form has the greatest excipient innovation potential?

The 20 mg dispersible tablet has greater potential because it requires rapid dispersion, acceptable taste, pediatric dose flexibility, and stable performance.

Is bedaquiline suitable for an oral suspension?

Bedaquiline can be investigated in suspension or granule systems, but the product must address solubility, dose uniformity, physical stability, food-effect instructions, and palatability.

Do Sirturo excipients create independent patent protection?

Most conventional excipients do not create meaningful standalone exclusivity. Protection may arise from a claimed combination, particle-engineering process, taste-masking system, manufacturing method, or dosage form.

Which excipient suppliers are most likely to benefit from Sirturo generic entry?

Suppliers of high-functionality disintegrants, direct-compression mannitol, pharmaceutical surfactants, pediatric flavor systems, and proprietary taste-masking technologies are best positioned to benefit.

References

  1. DailyMed. (2024). Sirturo: Bedaquiline fumarate tablet, film coated; bedaquiline fumarate tablet, dispersible. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

  2. U.S. Food and Drug Administration. (2024). Sirturo prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

  3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  4. U.S. Food and Drug Administration. (2024b). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.